- All sections
- C - Chemistry; metallurgy
- C07K - Peptides
- C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
Patent holdings for IPC class C07K 16/12
Total number of patents in this class: 2439
10-year publication summary
|
213
|
244
|
204
|
220
|
193
|
205
|
185
|
150
|
133
|
41
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Glaxosmithkline Biologicals S.A. | 1701 |
38 |
| Regeneron Pharmaceuticals, Inc. | 3650 |
36 |
| MedImmune, LLC | 467 |
35 |
| The Regents of the University of California | 18943 |
32 |
| Kymab Limited | 229 |
29 |
| Research Institute at Nationwide Children's Hospital | 481 |
29 |
| Merus N.V. | 185 |
25 |
| New York University | 1635 |
25 |
| Pfizer Inc. | 3322 |
23 |
| National Research Council of Canada | 1545 |
23 |
| The University of Chicago | 1282 |
23 |
| Wyeth LLC | 691 |
20 |
| Valneva Austria GmbH | 106 |
20 |
| Humabs Biomed SA | 115 |
18 |
| Griffith University | 143 |
17 |
| Institut Pasteur | 798 |
17 |
| Novartis AG | 11238 |
16 |
| Research Development Foundation | 234 |
15 |
| Dnae Group Holdings Limited | 71 |
14 |
| Boehringer Ingelheim Vetmedica GmbH | 1290 |
13 |
| Other owners | 1971 |